JP2013510852A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013510852A5 JP2013510852A5 JP2012538861A JP2012538861A JP2013510852A5 JP 2013510852 A5 JP2013510852 A5 JP 2013510852A5 JP 2012538861 A JP2012538861 A JP 2012538861A JP 2012538861 A JP2012538861 A JP 2012538861A JP 2013510852 A5 JP2013510852 A5 JP 2013510852A5
- Authority
- JP
- Japan
- Prior art keywords
- ophthalmic
- group
- propyl
- tetrahydro
- fluoren
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 Betapic Chemical compound 0.000 claims 14
- ALFVAHDVPGFPIK-GOSISDBHSA-N 2-[[(8ar)-3,4-dichloro-6-oxo-8a-propyl-8,9-dihydro-7h-fluoren-2-yl]oxy]acetic acid Chemical compound OC(=O)COC1=C(Cl)C(Cl)=C2C3=CC(=O)CC[C@]3(CCC)CC2=C1 ALFVAHDVPGFPIK-GOSISDBHSA-N 0.000 claims 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 229940090044 injection Drugs 0.000 claims 5
- 239000007924 injection Substances 0.000 claims 5
- 238000002347 injection Methods 0.000 claims 5
- 230000002911 mydriatic effect Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 4
- 229930182837 (R)-adrenaline Natural products 0.000 claims 4
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 claims 4
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims 4
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 4
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 claims 4
- WPVFJKSGQUFQAP-GKAPJAKFSA-N Valcyte Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 WPVFJKSGQUFQAP-GKAPJAKFSA-N 0.000 claims 4
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 claims 4
- 239000003732 agents acting on the eye Substances 0.000 claims 4
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims 4
- 229960000722 brinzolamide Drugs 0.000 claims 4
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 4
- OSRUSFPMRGDLAG-QMGYSKNISA-N dorzolamide hydrochloride Chemical compound [Cl-].CC[NH2+][C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 OSRUSFPMRGDLAG-QMGYSKNISA-N 0.000 claims 4
- 229960005139 epinephrine Drugs 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 claims 4
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims 4
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 claims 4
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 claims 4
- YTZALCGQUPRCGW-ZSFNYQMMSA-N verteporfin Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(CCC(=O)OC)=C(C)C(N3)=C3)=N2)C)=C(C=C)C(C)=C1C=C1C2=CC=C(C(=O)OC)[C@@H](C(=O)OC)[C@@]2(C)C3=N1 YTZALCGQUPRCGW-ZSFNYQMMSA-N 0.000 claims 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229940023490 ophthalmic product Drugs 0.000 claims 3
- 239000000049 pigment Substances 0.000 claims 3
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 claims 2
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 claims 2
- CHDPSNLJFOQTRK-LMOVPXPDSA-N (S)-betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OC[C@@H](O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-LMOVPXPDSA-N 0.000 claims 2
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 claims 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 229930003347 Atropine Natural products 0.000 claims 2
- WJTLIFNCKKFFLZ-UHFFFAOYSA-N BSS Chemical compound BSS WJTLIFNCKKFFLZ-UHFFFAOYSA-N 0.000 claims 2
- 108010001478 Bacitracin Proteins 0.000 claims 2
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- 108010088842 Fibrinolysin Proteins 0.000 claims 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 2
- 229930182566 Gentamicin Natural products 0.000 claims 2
- 108010026389 Gramicidin Proteins 0.000 claims 2
- 108010003272 Hyaluronate lyase Proteins 0.000 claims 2
- 102000001974 Hyaluronidases Human genes 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims 2
- JCMUOFQHZLPHQP-UHFFFAOYSA-N L-L-Ophthalmic acid Natural products OC(=O)CNC(=O)C(CC)NC(=O)CCC(N)C(O)=O JCMUOFQHZLPHQP-UHFFFAOYSA-N 0.000 claims 2
- FLOSMHQXBMRNHR-QPJJXVBHSA-N Methazolamide Chemical compound CC(=O)\N=C1\SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-QPJJXVBHSA-N 0.000 claims 2
- 229930193140 Neomycin Natural products 0.000 claims 2
- 239000004100 Oxytetracycline Substances 0.000 claims 2
- 108010093965 Polymyxin B Proteins 0.000 claims 2
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 claims 2
- 206010038848 Retinal detachment Diseases 0.000 claims 2
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 claims 2
- 229920002385 Sodium hyaluronate Polymers 0.000 claims 2
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 claims 2
- KIPLYOUQVMMOHB-MXWBXKMOSA-L [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O Chemical compound [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O KIPLYOUQVMMOHB-MXWBXKMOSA-L 0.000 claims 2
- 229940112258 acular Drugs 0.000 claims 2
- 229940070604 ak-con-a Drugs 0.000 claims 2
- 229940064582 akten Drugs 0.000 claims 2
- 229940003677 alphagan Drugs 0.000 claims 2
- 229940060610 alrex Drugs 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 230000001078 anti-cholinergic effect Effects 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 229940121375 antifungal agent Drugs 0.000 claims 2
- 239000003429 antifungal agent Substances 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 239000000607 artificial tear Substances 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 229960000396 atropine Drugs 0.000 claims 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims 2
- 229940120638 avastin Drugs 0.000 claims 2
- 229960004099 azithromycin Drugs 0.000 claims 2
- 229960003071 bacitracin Drugs 0.000 claims 2
- 229930184125 bacitracin Natural products 0.000 claims 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims 2
- 239000002876 beta blocker Substances 0.000 claims 2
- 229940097320 beta blocking agent Drugs 0.000 claims 2
- 229940064804 betadine Drugs 0.000 claims 2
- 229960004324 betaxolol Drugs 0.000 claims 2
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- 229960002470 bimatoprost Drugs 0.000 claims 2
- 229960003679 brimonidine Drugs 0.000 claims 2
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 claims 2
- 229960004484 carbachol Drugs 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 229960001139 cefazolin Drugs 0.000 claims 2
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 claims 2
- 230000008859 change Effects 0.000 claims 2
- 229960005091 chloramphenicol Drugs 0.000 claims 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 229940032491 cidofovir injection Drugs 0.000 claims 2
- 230000001886 ciliary effect Effects 0.000 claims 2
- 229960003405 ciprofloxacin Drugs 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229940069275 cosopt Drugs 0.000 claims 2
- 229930182912 cyclosporin Natural products 0.000 claims 2
- YHKBUDZECQDYBR-UHFFFAOYSA-L demecarium bromide Chemical compound [Br-].[Br-].C=1C=CC([N+](C)(C)C)=CC=1OC(=O)N(C)CCCCCCCCCCN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 YHKBUDZECQDYBR-UHFFFAOYSA-L 0.000 claims 2
- 239000003599 detergent Substances 0.000 claims 2
- 229960004875 difluprednate Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229940097575 durezol Drugs 0.000 claims 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims 2
- DLKYYJFLRUUGHJ-SSJCJZGYSA-A fomivirsen sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([S-])(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)[C@@H](OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 DLKYYJFLRUUGHJ-SSJCJZGYSA-A 0.000 claims 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims 2
- 229960002518 gentamicin Drugs 0.000 claims 2
- 229960004905 gramicidin Drugs 0.000 claims 2
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 229960002773 hyaluronidase Drugs 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229940004421 hylartin Drugs 0.000 claims 2
- 239000007943 implant Substances 0.000 claims 2
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 claims 2
- 229940083219 isopropyl unoprostone ophthalmic solution Drugs 0.000 claims 2
- 229960004130 itraconazole Drugs 0.000 claims 2
- 229960004384 ketorolac tromethamine Drugs 0.000 claims 2
- 229960001160 latanoprost Drugs 0.000 claims 2
- 229960004771 levobetaxolol Drugs 0.000 claims 2
- 229960004393 lidocaine hydrochloride Drugs 0.000 claims 2
- 229940080267 lotemax Drugs 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- 229940076783 lucentis Drugs 0.000 claims 2
- 229940112534 lumigan Drugs 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229940102129 muro 128 Drugs 0.000 claims 2
- 239000002637 mydriatic agent Substances 0.000 claims 2
- 229960005016 naphazoline Drugs 0.000 claims 2
- 229960004927 neomycin Drugs 0.000 claims 2
- 229940101054 neptazane Drugs 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229940099980 ocuflox Drugs 0.000 claims 2
- 229960001699 ofloxacin Drugs 0.000 claims 2
- JCMUOFQHZLPHQP-BQBZGAKWSA-N ophthalmic acid Chemical compound OC(=O)CNC(=O)[C@H](CC)NC(=O)CC[C@H](N)C(O)=O JCMUOFQHZLPHQP-BQBZGAKWSA-N 0.000 claims 2
- HVVLQPOCRDLFGA-UHFFFAOYSA-N ophthalmic acid Natural products CCC(NC(=O)C(N)CCC(=O)O)C(=O)NCC(=O)O HVVLQPOCRDLFGA-UHFFFAOYSA-N 0.000 claims 2
- 108010088490 ophthalmic acid Proteins 0.000 claims 2
- 229940054534 ophthalmic solution Drugs 0.000 claims 2
- 239000002997 ophthalmic solution Substances 0.000 claims 2
- 229940074731 ophthalmologic surgical aids Drugs 0.000 claims 2
- 229960000625 oxytetracycline Drugs 0.000 claims 2
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims 2
- 235000019366 oxytetracycline Nutrition 0.000 claims 2
- HIANJWSAHKJQTH-UHFFFAOYSA-N pemirolast Chemical compound CC1=CC=CN(C2=O)C1=NC=C2C=1N=NNN=1 HIANJWSAHKJQTH-UHFFFAOYSA-N 0.000 claims 2
- 229960004439 pemirolast Drugs 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229960001802 phenylephrine Drugs 0.000 claims 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims 2
- 229960001416 pilocarpine Drugs 0.000 claims 2
- 229920000024 polymyxin B Polymers 0.000 claims 2
- 229960005266 polymyxin b Drugs 0.000 claims 2
- 229960005205 prednisolone Drugs 0.000 claims 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229960003981 proparacaine Drugs 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 claims 2
- 229960003876 ranibizumab Drugs 0.000 claims 2
- 229940053174 restasis Drugs 0.000 claims 2
- 230000004264 retinal detachment Effects 0.000 claims 2
- 229940081623 rose bengal Drugs 0.000 claims 2
- 229930187593 rose bengal Natural products 0.000 claims 2
- AZJPTIGZZTZIDR-UHFFFAOYSA-L rose bengal Chemical compound [K+].[K+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 AZJPTIGZZTZIDR-UHFFFAOYSA-L 0.000 claims 2
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 229940010747 sodium hyaluronate Drugs 0.000 claims 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 229960004492 suprofen Drugs 0.000 claims 2
- 229940063650 terramycin Drugs 0.000 claims 2
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims 2
- 229960004605 timolol Drugs 0.000 claims 2
- 229960000707 tobramycin Drugs 0.000 claims 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 2
- 229960005294 triamcinolone Drugs 0.000 claims 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 2
- 229960003962 trifluridine Drugs 0.000 claims 2
- 229960004791 tropicamide Drugs 0.000 claims 2
- 229940108420 trusopt Drugs 0.000 claims 2
- 229950008081 unoprostone isopropyl Drugs 0.000 claims 2
- 229940010343 valcyte Drugs 0.000 claims 2
- 229960002149 valganciclovir Drugs 0.000 claims 2
- 229960003895 verteporfin Drugs 0.000 claims 2
- 229960003636 vidarabine Drugs 0.000 claims 2
- 229940099269 viroptic Drugs 0.000 claims 2
- 229940032699 vistide Drugs 0.000 claims 2
- 229940061392 visudyne Drugs 0.000 claims 2
- 229940054953 vitrase Drugs 0.000 claims 2
- 229940053728 vitrasert Drugs 0.000 claims 2
- 229940002639 xalatan Drugs 0.000 claims 2
- 229940061636 zaditor Drugs 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- KUMVUWRLEVNPTJ-UHFFFAOYSA-N 5,6-dichloro-7-(1,3-oxazinan-2-ylmethoxy)-9a-propyl-2,9-dihydro-1h-fluoren-3-one Chemical compound ClC=1C(Cl)=C2C(=CC(=O)CC3)C3(CCC)CC2=CC=1OCC1NCCCO1 KUMVUWRLEVNPTJ-UHFFFAOYSA-N 0.000 claims 1
- ZQBXJZNHWDNUHC-UHFFFAOYSA-N 5,6-dichloro-7-(4,5-dihydro-1,3-oxazol-2-ylmethoxy)-9a-propyl-2,9-dihydro-1h-fluoren-3-one Chemical compound ClC=1C(Cl)=C2C(=CC(=O)CC3)C3(CCC)CC2=CC=1OCC1=NCCO1 ZQBXJZNHWDNUHC-UHFFFAOYSA-N 0.000 claims 1
- ZGVTYIPPUSNWGV-UHFFFAOYSA-N 5,6-dichloro-7-(4,5-dihydro-1,3-thiazol-2-ylmethoxy)-9a-propyl-2,9-dihydro-1h-fluoren-3-one Chemical compound ClC=1C(Cl)=C2C(=CC(=O)CC3)C3(CCC)CC2=CC=1OCC1=NCCS1 ZGVTYIPPUSNWGV-UHFFFAOYSA-N 0.000 claims 1
- JYWWIUCVQSCRAN-UHFFFAOYSA-N 5,6-dichloro-7-[[2-(4,5-dihydro-1,3-oxazol-2-yl)phenyl]methoxy]-9a-propyl-2,9-dihydro-1h-fluoren-3-one Chemical compound ClC=1C(Cl)=C2C(=CC(=O)CC3)C3(CCC)CC2=CC=1OCC1=CC=CC=C1C1=NCCO1 JYWWIUCVQSCRAN-UHFFFAOYSA-N 0.000 claims 1
- RDTSQFPTPAGTNB-UHFFFAOYSA-N 5,6-dichloro-7-[[3-(4,5-dihydro-1,3-oxazol-2-yl)phenyl]methoxy]-9a-propyl-2,9-dihydro-1h-fluoren-3-one Chemical compound ClC=1C(Cl)=C2C(=CC(=O)CC3)C3(CCC)CC2=CC=1OCC(C=1)=CC=CC=1C1=NCCO1 RDTSQFPTPAGTNB-UHFFFAOYSA-N 0.000 claims 1
- JVBBXJQBOHKQFC-UHFFFAOYSA-N 5,6-dichloro-7-[[4-(4,5-dihydro-1,3-oxazol-2-yl)phenyl]methoxy]-9a-propyl-2,9-dihydro-1h-fluoren-3-one Chemical compound ClC=1C(Cl)=C2C(=CC(=O)CC3)C3(CCC)CC2=CC=1OCC(C=C1)=CC=C1C1=NCCO1 JVBBXJQBOHKQFC-UHFFFAOYSA-N 0.000 claims 1
- OVQJPEXXKQBZHV-UHFFFAOYSA-N 5,6-dichloro-9a-propyl-7-(pyridin-2-ylmethoxy)-2,9-dihydro-1h-fluoren-3-one Chemical compound ClC=1C(Cl)=C2C(=CC(=O)CC3)C3(CCC)CC2=CC=1OCC1=CC=CC=N1 OVQJPEXXKQBZHV-UHFFFAOYSA-N 0.000 claims 1
- BZSIKOORTKXVHC-UHFFFAOYSA-N 5,6-dichloro-9a-propyl-7-(pyridin-3-ylmethoxy)-2,9-dihydro-1h-fluoren-3-one Chemical compound ClC=1C(Cl)=C2C(=CC(=O)CC3)C3(CCC)CC2=CC=1OCC1=CC=CN=C1 BZSIKOORTKXVHC-UHFFFAOYSA-N 0.000 claims 1
- YRYUWMMIJIENST-UHFFFAOYSA-N 5,6-dichloro-9a-propyl-7-(pyridin-4-ylmethoxy)-2,9-dihydro-1h-fluoren-3-one Chemical compound ClC=1C(Cl)=C2C(=CC(=O)CC3)C3(CCC)CC2=CC=1OCC1=CC=NC=C1 YRYUWMMIJIENST-UHFFFAOYSA-N 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims 1
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 1
- 206010047571 Visual impairment Diseases 0.000 claims 1
- 230000004075 alteration Effects 0.000 claims 1
- 230000003444 anaesthetic effect Effects 0.000 claims 1
- 229940035674 anesthetics Drugs 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 229940006387 azasite Drugs 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000011325 dry age related macular degeneration Diseases 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- 125000004969 haloethyl group Chemical group 0.000 claims 1
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims 1
- 229940125702 ophthalmic agent Drugs 0.000 claims 1
- 230000001769 paralizing effect Effects 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 229920002545 silicone oil Polymers 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 208000029257 vision disease Diseases 0.000 claims 1
- 230000004304 visual acuity Effects 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
- 230000004382 visual function Effects 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26043909P | 2009-11-12 | 2009-11-12 | |
| US61/260,439 | 2009-11-12 | ||
| US37862410P | 2010-08-31 | 2010-08-31 | |
| US61/378,624 | 2010-08-31 | ||
| PCT/US2010/055540 WO2011059881A1 (en) | 2009-11-12 | 2010-11-05 | Treatment of ophthalmic conditions with fluorenone derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013510852A JP2013510852A (ja) | 2013-03-28 |
| JP2013510852A5 true JP2013510852A5 (cg-RX-API-DMAC7.html) | 2013-12-26 |
Family
ID=43991966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012538861A Pending JP2013510852A (ja) | 2009-11-12 | 2010-11-05 | フルオレノン誘導体による眼の病態の治療 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20130189246A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2501227A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2013510852A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011059881A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9333202B2 (en) | 2012-05-01 | 2016-05-10 | The Trustees Of Columbia University In The City Of New York | Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease |
| EP2968303B1 (en) | 2013-03-14 | 2018-07-04 | The Trustees of Columbia University in the City of New York | Octahydrocyclopentapyrroles, their preparation and use |
| US10273243B2 (en) | 2013-03-14 | 2019-04-30 | The Trustees Of Columbia University In The City Of New York | 4-phenylpiperidines, their preparation and use |
| US9938291B2 (en) | 2013-03-14 | 2018-04-10 | The Trustess Of Columbia University In The City Of New York | N-alkyl-2-phenoxyethanamines, their preparation and use |
| WO2014151936A1 (en) | 2013-03-14 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | Octahydropyrrolopyrroles, their preparation and use |
| AU2015253232B2 (en) | 2014-04-30 | 2020-10-01 | The Trustees Of Columbia University In The City Of New York | Substituted 4-phenylpiperidines, their preparation and use |
| US11000492B2 (en) | 2015-11-13 | 2021-05-11 | The Trustees Of Columbia University In The City Of New York | Fluorenone compound for the treatment of gout |
| US20250127760A1 (en) * | 2021-12-28 | 2025-04-24 | Shenyang Xingqi Pharmaceutical Co., Ltd. | Composition and use thereof in preparation of medicament for treating presbyopia |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5857319A (ja) * | 1981-09-30 | 1983-04-05 | Green Cross Corp:The | 高粘性ヒアルロン酸製剤 |
| JPH06145045A (ja) * | 1992-11-05 | 1994-05-24 | Koken Co Ltd | 網膜剥離治療用シリコ−ンオイル及びその製造方法 |
| US6251898B1 (en) * | 1999-08-24 | 2001-06-26 | Questcor Pharmaceuticals, Inc. | Medical use of fluorenone derivatives for treating and preventing brain and spinal injury |
| US7186707B2 (en) * | 2002-04-01 | 2007-03-06 | University Of Florida | Prodrugs for use as ophthalmic agents |
| CA2622312A1 (en) * | 2006-01-30 | 2007-08-02 | (Osi) Eyetech, Inc. | Combination therapy for the treatment of neovascular disorders |
-
2010
- 2010-11-05 JP JP2012538861A patent/JP2013510852A/ja active Pending
- 2010-11-05 WO PCT/US2010/055540 patent/WO2011059881A1/en not_active Ceased
- 2010-11-05 US US13/509,712 patent/US20130189246A1/en not_active Abandoned
- 2010-11-05 EP EP10830543.4A patent/EP2501227A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013510852A5 (cg-RX-API-DMAC7.html) | ||
| US20240207246A1 (en) | Pharmaceutical composition | |
| JP6865254B2 (ja) | 眼疾患を処置するための組成物、製剤、および方法 | |
| CA2766033C (en) | Prodrugs of nh-acidic compounds | |
| TWI755356B (zh) | 含檸檬酸酯之緩釋劑之用途 | |
| JP2013502460A5 (cg-RX-API-DMAC7.html) | ||
| JP2017503835A5 (cg-RX-API-DMAC7.html) | ||
| RU2016133980A (ru) | Композиции и способы для лечения заболеваний глаз | |
| NZ610230A (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
| CN1132580C (zh) | 治疗眼病的喹诺酮衍生物 | |
| JP2021503449A5 (cg-RX-API-DMAC7.html) | ||
| WO2008020032A8 (en) | Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases | |
| US20130189246A1 (en) | Treatment of ophthalmic conditions with fluorenone derivatives | |
| JP2010514733A5 (cg-RX-API-DMAC7.html) | ||
| WO2009109501A2 (en) | Ocular pharmaceutical compositions | |
| JP2017527600A5 (cg-RX-API-DMAC7.html) | ||
| CA2909111A1 (en) | The local treatment of inflammatory ophthalmic diseases | |
| JP2015505536A5 (cg-RX-API-DMAC7.html) | ||
| JP2021138710A5 (cg-RX-API-DMAC7.html) | ||
| CA3036474C (en) | Therapeutic agent for an ophthalmic disease comprising a vegf receptor inhibitor | |
| WO2024243373A1 (en) | Cysteine derivatives for the treatment of presbyopia | |
| JPWO2021125800A5 (cg-RX-API-DMAC7.html) | ||
| RU2007112885A (ru) | Способ лечения глазных заболеваний | |
| Wirtschafter | Current Ophthalmology and Medicine | |
| HK1246167A1 (en) | Depot preparation containing citric acid ester |